The purpose of this study is to examine the safety, tolerability, and PK of various increasing single and multiple doses of VBP15 in healthy adult subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
86
PRA Health Sciences
Lenexa, Kansas, United States
Number of Subjects With Adverse Effects After a Single Dose of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 15 days
Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)
Time frame: Participants will be followed for the duration of hospital stay of 15 days
Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 15 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.